ABOS (Acumen Pharmaceuticals) Total Enterprise Value

Official company branding of acumenpharm.com (ABOS)

This price chart for Acumen Pharmaceuticals (ABOS) demonstrates a business valuation that currently stands at 111.11. Acumen Pharmaceuticals (ABOS) develops Alzheimer's disease therapies, which will provide the company with immense pricing power should its developments succeed. Revenues will be based on the commercialization of antibodies (sabinezumab) to combat brain degeneration. The continuity of raw material supplies is guaranteed by strict aviation controls and proven carriers.

ABOS (Acumen Pharmaceuticals, Inc) Total Company Value history from 11/23/2025 to 10/28/2026

Acumen Pharmaceuticals (ABOS) - metric breakdowns and financial figures

- price and consensus price forecast:
Price Chart Acumen Pharmaceuticals Inc.|ABOS - Price Target Chart
- market capitalization data:
Market Value Acumen Pharmaceuticals|ABOS - Total Company Value
- book capitalization data:
Net Assets per Share Acumen Pharmaceuticals|ABOS - Company Book Value|Capitalization to Book Value Ratio acumenpharm.com|ABOS - Company Total Assets
- debt and liquidity data:
Debt to Capital Acumen Pharmaceuticals|ABOS - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital acumenpharm.com|ABOS - Company Debts|Debt to Net Assets Ratio Acumen Pharmaceuticals
Comprehensive company analysis:Acumen Pharmaceuticals Inc. (ABOS)
Mass-produced product of Acumen Pharmaceuticals

The selection of promising issuers is based on an analysis of valuation multiples. This indicator determines the total buyout price of a business by summing market capitalization and net debt. For Acumen Pharmaceuticals (ABOS), this metric reflects the real value of assets, including the commercialization potential of Alzheimer's disease therapy. An investor can assess price fairness through the enterprise value metric. This trend captures the risk of overpayment in a timely manner.

Direct competitors

Biogen Inc - Total Company Value|NBIX (Neurocrine Biosciences Inc) - Total Company Value|RGC: Total Enterprise Value|Axsome Therapeutics - Total Company Value|ACAD (acadia-pharm.com) - Company Buyout Price|Total Company Value Xenon (XENE)|Business Value Viking Therapeutics Inc|Supernus Pharma - Enterprise Value|Total Enterprise Value Catalyst Corp CPRX|Real Price to Acquire Entire Company DNLI (Denali Therapeutics)|harmonybiosciences.com - Enterprise Value|Total Company Value Biohaven (BHVN)|AMLX: Value Adjusted for Debt and Cash|Total Company Value TRVI|Praxis Corp (PRAX) - Total Enterprise Value|AVXL (Anavex Life Sciences) - Enterprise Value|Enterprise Value ceribell.com|Enterprise Value PRTA (Prothena Biosciences)|Real Price to Acquire Entire Company alector.com ALEC|Real Price to Acquire Entire Company ANNX (Annexon Inc.)|Omeros Corp - Enterprise Value|NGNE: Total Company Value|ACIU - Real Price to Acquire Entire Company|Enterprise Value VYGR|NMRA (Neumora) - Total Enterprise Value|Total Company Value Scilex Holding Co. (SCLX)|Business Value Tevogen Bio Inc. (TVGN)|Alpha Cognition (ACOG) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash CGTX (Cognition Therapeutics Inc.)|Inhibikase Therapeutics, Inc. (IKT) - Total Company Value|Full Business Value Cassava Sciences Inc SAVA|Enterprise Value Assertio Therapeutics (ASRT)|COYA - Value Adjusted for Debt and Cash|VTGN: Enterprise Value|OVID (Ovid Therapeutics) - Enterprise Value|CRVO - Total Company Value|Value Adjusted for Debt and Cash ATHE|Total Company Value CLNN (Clene Inc.)|Real Price to Acquire Entire Company pepgen.com (PEPG)|Enterprise Value JUNS (Jupiter Neurosciences)|Enterprise Value relmada.com RLMD|ANVS: Enterprise Value|GRCE - Real Price to Acquire Entire Company|Enterprise Value AIFF|Total Enterprise Value Klotho Neurosciences|NRSN (NeuroSense Therapeutics Ltd) - Real Price to Acquire Entire Company|Enterprise Value revivapharma.com (RVPH)|Real Price to Acquire Entire Company MetaVia Inc|Aggregate Business Value NeurAxis Inc. (NRXS)|Enterprise Value HSDT|Company Buyout Price Passage Bio Inc. PASG|NEUP: Enterprise Value|NERV - Real Price to Acquire Entire Company|ATHA: Enterprise Value|ADXN (Addex Therapeutics Ltd.) - Enterprise Value|Total Company Value Alzamend Neuro Inc.|Total Company Value CYCN|PTIX (Protagenic Therapeutics) - Total Company Value|Company Buyout Price pasitheaclinics.com (KTTA)|Enterprise Value CRGT (Cortigent)|Enterprise Value Avenue Therapeutics Inc. ATXI|BCLI - Enterprise Value|CARA: Total Company Value|Total Company Value CHRO|ELYM (Eliem Therapeutics Inc.) - Total Enterprise Value|ITCI: Total Company Value|Company Buyout Price LBPH|Total Company Value Marinus MRNS|Business Value NKGen Biotech Corp (NKGN)|NRBO: Enterprise Value|SAGE - Total Enterprise Value|Synaptogenix - Real Price to Acquire Entire Company|TRVN: Enterprise Value|Total Company Value vigilneuro.com VIGL|WENA (anewmeds.com) - Value Adjusted for Debt and Cash|Total Company Value CERE (Cerevel Therapeutics)